Sano et al. reported that patients with type 2 diabetes treated with a SGLT2 inhibitor exhibit increased grip strength, indicating that SGLT2i treatment does not necessarily promote muscle weakness, a typical symptom of sarcopenia, but rather strengthens it.57 Long-term use of SGLT2i could rescue fat and glycogen synthesis and energy storage in skeletal muscle by improving insulin sensitivity and preserving endogenous insulin secretion, an effect that might antagonize increased lipolysis or muscle catabolism. This evidence concerns the gene SLC5A2 and sarcopenia.